Tekla Life Sciences Investors (HQL) Income Statement
HQL FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsHQL revenue and net income
Where HQL's revenue goes
FY2025Each bar shows an amount and its share of revenue. HQL kept 99.1% of revenue as net income.
HQL profit margins
HQL growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −0.3% | — | −7.0% | +51.9% |
| Gross profit | −0.3% | — | −7.0% | — |
| Operating income | +0.3% | — | −7.0% | — |
| Net income | +0.3% | — | −7.0% | +7.8% |
| EPS (diluted) | +124.6% | — | −18.7% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
HQL quarterly EPS vs estimates
Tekla Life Sciences Investors beat the analyst EPS estimate in 2 of the last 4 quarters.
HQL income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $86.4M | $86.7M | $23.5M | $0 | $65.7M | $124.1M | $0 | $2.0M | $69.8M | $6.3M |
| Cost of revenue | $5.0M | $5.4M | $5.2M | $5.5M | $5.6M | $4.8M | $4.5M | $4.8M | $4.6M | $4.9M |
| Gross profit | $86.4M | $86.7M | $23.5M | −$103.3M | $65.7M | $124.1M | −$69.3M | $2.0M | $65.2M | $1.3M |
| Research & development | — | — | $1 | $3 | $1 | $3 | — | — | $1 | $2 |
| Sales, general & admin | $743,171 | $1.3M | $903,138 | $1.1M | $844,018 | $751,317 | $876,764 | $5.6M | $991,511 | $5.2M |
| Total operating expenses | $791,573 | $1.4M | $1.2M | $1.4M | $1.2M | $1.0M | $1.1M | $5.6M | $1.3M | $13.3M |
| Operating income | $85.6M | $85.3M | $22.4M | −$104.6M | $64.5M | $123.1M | −$70.5M | −$3.6M | −$3.9M | −$3.8M |
| Interest income | $349,835 | $1.0M | $204,449 | $50,092 | $68.7M | $164,800 | $67.6M | $32.3M | $72.4M | $8.1M |
| Interest expense | — | — | — | — | $0 | $0 | $67.6M | $32.3M | $72.4M | $8.1M |
| Income before taxes | $85.6M | $85.3M | $22.4M | −$104.6M | $64.5M | $123.1M | −$70.5M | $28.7M | $68.6M | −$11.9M |
| Income taxes | — | — | $22.4M | −$3.0M | −$4.1M | −$2.1M | −$2.9M | $1 | $3 | $26.3M |
| Net income | $85.6M | $85.3M | $22.4M | −$104.6M | $64.5M | $123.1M | −$70.5M | $28.7M | $68.6M | −$11.9M |
| EBITDA | $85.6M | $87.2M | $22.4M | −$104.6M | $64.5M | $123.1M | −$70.5M | $60.9M | $68.6M | −$20.0M |
| EPS (diluted) | $2.74 | $1.22 | $0.82 | −$4.11 | $3.94 | $7.71 | −$4.59 | $1.85 | $4.77 | −$1.09 |
| Gross margin | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | — | 100.0% | 93.4% | 21.3% |
| Operating margin | 99.1% | 98.4% | 95.0% | — | 98.2% | 99.2% | — | −181.6% | −5.6% | −60.3% |
| Net margin | 99.1% | 98.4% | 95.0% | — | 98.2% | 99.2% | — | 1,443.4% | 98.2% | −189.3% |
| Mar '26 | Sep '25 | Mar '25 | Sep '24 | Mar '24 | Dec '23 | Sep '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.1M | $11.6M | $18.2M | $1.9M | $2.1M | $2.1M | $29.6M | $1.9M | $965 | $21.7M | $792 | $10.2M |
| Cost of revenue | $3.1M | $2.4M | $2.5M | $2.8M | $2.5M | $2.5M | $2.6M | $2.7M | $0 | $2.6M | $0 | $2.9M |
| Gross profit | $45.0M | $9.2M | $15.7M | $1.9M | $2.1M | $2.1M | $27.0M | $1.9M | $965 | $19.0M | $792 | $7.3M |
| Sales, general & admin | $3.3M | $743,171 | $2.7M | $3.2M | $2.7M | $2.7M | $2.0M | $2.9M | $1,435 | $1.4M | $1,443 | $1,562 |
| Total operating expenses | −$20.4M | −$123.6M | $62.9M | $3.2M | $2.7M | $2.7M | $38.4M | $2.9M | $15,936 | $14.9M | $14,945 | $38,865 |
| Operating income | $65.3M | $132.8M | −$47.2M | −$1.3M | −$653,336 | −$653,336 | −$11.4M | −$940,748 | −$470 | −$28.3M | −$651 | −$76.3M |
| Interest income | — | — | — | — | — | — | — | — | — | — | — | $74.6M |
| Income before taxes | $65.3M | $132.8M | −$47.2M | $35.0M | $50.3M | $50.3M | −$11.5M | $33.8M | $16,901 | −$28.3M | −$14,153 | −$76.3M |
| Income taxes | — | — | — | — | −$326,667 | $25.5M | −$43,812 | $43,812 | $17.4M | −$651,140 | −$13.5M | −$844 |
| Net income | $65.3M | $132.8M | −$47.2M | $35.0M | $50.3M | $50.3M | −$11.5M | $33.8M | $16,901 | −$28.3M | −$14,153 | −$76.3M |
| EBITDA | $65.3M | $132.8M | −$45.9M | $35.0M | $100.5M | $101.2M | −$10.2M | $33.8M | $17,371 | −$27.0M | −$13,502 | −$74.6M |
| EPS (diluted) | — | $4.38 | −$1.64 | $1.22 | — | — | — | — | — | −$1.08 | — | −$3.03 |
| Gross margin | 93.5% | 79.0% | 86.1% | 100.0% | 100.0% | 100.0% | 91.2% | 100.0% | 100.0% | 87.8% | 100.0% | 71.4% |
| Operating margin | 135.9% | 1,141.8% | −259.5% | −66.2% | −31.6% | −31.6% | −38.7% | −48.8% | −48.8% | −130.5% | −82.2% | −750.1% |
| Net margin | 135.9% | 1,141.8% | −259.5% | 1,830.0% | 2,433.4% | 2,433.4% | −38.7% | 1,752.1% | 1,752.1% | −130.5% | −1,787.5% | −750.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in HQL's financial statements (latest annual report filed September 30, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
HQL financial results
In fiscal year 2025 (ended September 30, 2025), Tekla Life Sciences Investors reported revenue of $86.4 million, down 0.3% from the year before. It had net income of $85.6 million (up 0.3%), a net profit margin of 99.1%. Diluted earnings per share came to $2.74. Over five years revenue grew at an average rate of −7.0% a year.
See the HQL stock overview for the latest quote and news, or the HQL chart for price history and technical indicators.
HQL income statement FAQ
What is Tekla Life Sciences Investors's annual revenue?
Tekla Life Sciences Investors reported total revenue of $86.4 million for fiscal year 2025, which ended on September 30, 2025. That was down 0.3% from $86.7 million the previous year.
Is Tekla Life Sciences Investors profitable?
Yes. Tekla Life Sciences Investors reported net income of $85.6 million in fiscal 2025, a net profit margin of 99.1%; its operating margin was 99.1%.
What is Tekla Life Sciences Investors's gross margin?
Tekla Life Sciences Investors's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Tekla Life Sciences Investors kept $100 after the direct cost of its products and services.
How fast is Tekla Life Sciences Investors growing?
Revenue grew −7.0% a year on average over the last five fiscal years, from $124.1 million to $86.4 million.
What are Tekla Life Sciences Investors's earnings per share?
Tekla Life Sciences Investors earned $2.74 per diluted share in fiscal 2025, compared with $1.22 a year earlier.
When does Tekla Life Sciences Investors's fiscal year end?
Tekla Life Sciences Investors's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on September 30, 2025.